Children's oncology Group's 2013 blueprint for research: Rare tumors

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 1016-1021

  Rodriguez Galindo, Carlos ^a   Krailo, Mark ^b   Frazier, Lindsay ^a   Chintagumpala, Murali ^c   Amatruda, James ^d   Katzenstein, Howard ^e   Malogolowkin, Marcio ^f   Spector, Logan ^g   Pashankar, Farzana ^h   Meyers, Rebecka ⁱ   Tomlinson, Gail ^j  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^f UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

Germ cell tumors; Hepatoblastoma; Rare cancers; Retinoblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; PACLITAXEL;

ADVANCED CANCER; CANCER EPIDEMIOLOGY; CANCER STAGING; CHILDHOOD CANCER; EVIDENCE BASED MEDICINE; GERM CELL TUMOR; HUMAN; LIVER TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RARE DISEASE; RETINOBLASTOMA; REVIEW; UNSPECIFIED SIDE EFFECT;

CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; INCIDENCE; NEOPLASMS; RARE DISEASES; RESEARCH;

EID: 84876441093     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24428     Document Type: Review

References (41)

1. Ries LAG, Smith MA, Gurney JG, et al. (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.
2. Rodriguez-Galindo C, Chantada GL, Haik B, et al. Retinoblastoma: Current treatment and future perspectives. Curr Treat Options Neurol 2007; 9: 294-307.
3. Meyers RL. Tumors of the liver in children. Surg Oncol 2007; 16: 195-203.
4. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012; 59: 776-779.
5. Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. Pediatr Blood Cancer 2012; 59: 785-792.
6. Trobaugh-Lotrario AD, Katzenstein HM. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: Past, present, and future strategies. Pediatr Blood Cancer 2012; 59: 809-812.
7. Meyers RL, Czauderna P, Otte J-B. Surgical treatment of hepatoblastoma. Pediatr Blood Cancer 2012; 59: 800-808.
8. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A Pediatric Intergroup Study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004; 22: 2691-2700.
9. Rogers PC, Olson TA, Cullen JW, et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study-Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 2004; 22: 3563-3569.
10. Pappo AS, Krailo M, Chen Z, et al. Infrequent tumor initiative of the children's oncology group: Initial lessons learned and their impact on future plans. J Clin Oncol 2010; 28: 5011-5016.
11. Murphree AL. Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin N Am 2005; 18: 41-53.
12. Chantada G, Doz F, Antonelli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006; 801-805.
13. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: A report from the children's oncology group. Pediatr Blood Cancer 2009; 53: 1016-1022.
14. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002; 120: 1653-1658.
15. Gobin Y, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: Four-year experience. Arch Ophthalmol 2011; 129: 732-737.
16. Dunkel IJ, Chan HSL, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer 2010; 55: 149-152.
17. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 2005; 23: 2272-2279.
18. Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: Pediatric Oncology Group/children's cancer group intergroup study. J Clin Oncol 1999; 17: 2137-2143.
19. Mann JR, Raafat F, Robinson K, et al. The United Kingdom children's cancer study group's second germ cell tumor study: Carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18: 3809-3818.
20. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new international society of pediatric oncology boston ototoxicity scale. J Clin Oncol 2012; 30: 2408-2417.
21. Fligor BJ, Krasker JD, Villaluna D, et al. "Accelerated ear-age": A new measure of chemotherapy-induced ototoxicity. Pediatr Blood Cancer 2012; 59: 947-949.
22. Cheuk DKL, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 2011; 117: 197-206.
23. Sultan I, Casanova M, Ferrari A, et al. Differential features of nasopharyngeal carcinoma in children and adults: A SEER study. Pediatr Blood Cancer 2010; 55: 279-284.
24. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, et al. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 2005; 45: 265-273.
25. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66.
26. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-334.
27. Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic evaluation of a large series of hepatoblastomas: Numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 2005; 44: 177-184.
28. Kumon K, Kobayashi H, Namiki T, et al. Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: Cytogenetic and comparative genomic hybridization analysis. Jpn J Cancer Res 2001; 92: 854-862.
29. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009; 52: 328-334.
30. West JA, Viswanathan SR, Yabuuchi A, et al. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 2009; 460: 909-913.
31. Neumann JC, Chandler GL, Damoulis VA, et al. Mutation in the type IB bone morphogenetic protein receptor alk6b impairs germ-cell differentiation and causes germ-cell tumors in zebrafish. Proc Natl Acad Sci 2011; 108: 13153-13158.
32. Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. Cancer 2009; 115: 5828-5835.
33. Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the children's oncology group. J Clin Oncol 2011; 29: 3301-3306.
34. Puumala SE, Ross JA, Feusner JH, et al. Parental infertility, infertility treatment and hepatoblastoma: A report from the Children's Oncology Group. Hum Reprod 2012; 27: 1649-1656.
35. Otte J-B, Meyers R. PLUTO First report. Pediatr Transplant 2010; 14: 830-835.
36. Sposto R. Cure model analysis in cancer: An application to data from the Children's Cancer Group. Stat Med 2002; 21: 293-312.
37. Nicholson J. Prognostic Classification of Pediatric Germ Cell Tumors. In: 44th Congress of the International Society of Paediatric Oncology, London, UK, 2012.
38. Hale J. Carboplatin (CBP) is equivalent to cisplatin (CP) within prognostic groups in paediatric extracranial malignant germ cell tumours (MGCTs). In: American Society of Clinical Oncology, Chicago, IL, 2012.
39. Ribeiro RC, Pinto EM, Zambetti GP, et al. The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol 2012; 351: 37-43.
40. Straathof KCM, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-1904.
41. Woolson RF. Rank tests and a one-sample log rank test for comparing observed survival to a standard population. Biometrics 1981; 37: 687-696.